Diabetes drug class carries risk

According to a recent report from two faculty members at the Wake Forest University School a class of oral drugs for type 2 diabetes could have the potential to make heart failure worse. The report was published in Heart.
Sonal Singh (assistant professor of internal medicine) and Curt Furberg (professor of public health sciences) were reported as commenting: “We strongly recommend restrictions in the use of thiazolidinediones (the class of drugs) and question the rationale for leaving rosiglitazone on the market.”
Thiazolidinedione as a category includes Rosiglitazone and Pioglitazone. Singh and Furberg reportedly said: “At this time, justification for use of thiazolidinediones is very weak to non-existent.”
The drugs were tested in three trials called ACCORD, ADVANCE and the Veterans Affairs Diabetes study. Singh reportedly concluded: “Safer, cheaper and more effective treatment alternatives are available that do not carry these negative cardiovascular risks in patients with diabetes . The rationale for the use of the thiazolidinediones is unclear.”

To Top